Physician profile
Karl E Harbin
NPI 1295721157
$2,315.22
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $149 · 2022: $991 · 2023: $355 · 2024: $19.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.20 | 2019-2023 | |
| Astellas Pharma US INC | $192.37 | 2019-2024 | Veozah, Myrbetriq |
| Roche Diagnostics Corporation | $186.00 | 2019-2020 | |
| Pfizer INC. | $144.60 | 2019-2023 | |
| Amgen INC. | $124.02 | 2019-2023 | Prolia, Evenity |
| Hologic Sales and Service, LLC | $121.34 | 2019-2023 | Aptima, Novasure |
| Sumitomo Pharma America, INC. | $118.41 | 2023 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $110.53 | 2022 | |
| Organon LLC | $99.93 | 2022-2023 | Nexplanon |
| Scynexis, INC. | $89.10 | 2022 | |
| Daiichi Sankyo INC. | $80.42 | 2019 | |
| Mayne Pharma Commercial LLC | $80.26 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.81 | 2019-2022 | |
| Urovant Sciences INC | $52.94 | 2022 | |
| Evofem Biosciences, INC. | $49.44 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $46.18 | 2019-2020 | |
| Exeltis, USA INC. | $38.38 | 2022-2023 | Slynd |
| Merck Sharp & Dohme LLC | $35.56 | 2019 | |
| Avion Pharmaceuticals | $32.93 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.95 | 2022 | |
| Minerva Surgical, INC | $31.65 | 2019-2023 | |
| Vertical Pharmaceuticals, LLC | $29.77 | 2019 | |
| Mylan Pharmaceuticals INC. | $29.02 | 2019-2022 | |
| Duchesnay USA Incorporated | $28.41 | 2019 | |
| Becton, Dickinson and Company | $28.25 | 2022 | |
| Amag Pharmaceuticals, INC. | $26.62 | 2019 | |
| Therapeuticsmd, INC. | $26.40 | 2019-2022 | |
| Allergan, INC. | $26.05 | 2019-2020 | |
| Kci USA, INC. | $24.20 | 2019 | |
| Axonics, INC. | $20.87 | 2023 | Axonics |
| Sage Therapeutics, LLC | $19.14 | 2019 | |
| Intuitive Surgical, INC. | $17.11 | 2019 | |
| Gilead Sciences, INC. | $16.68 | 2019 | |
| Shield Therapeutics INC | $15.68 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Harbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.